{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:39:35Z","timestamp":1791203975243,"version":"4.2.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jpba.2021.114299","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T11:54:10Z","timestamp":1627991650000},"page":"114299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Determination of serum carbamazepine and its metabolite by validated tandem mass spectrometric method and the effect of carbamazepine on various hematological and biochemical parameters"],"prefix":"10.1016","volume":"205","author":[{"given":"Duygu","family":"Eryavuz Onmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedat","family":"Abusoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahadir","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsum","family":"Abusoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Humeyra","family":"Yerlikaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jpba.2021.114299_bib0005","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3390\/ph3072090","article-title":"Difficulties in treatment and management of epilepsy and challenges in new drug development","volume":"3","author":"Wahab","year":"2010","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.jpba.2021.114299_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.31887\/DCNS.2008.10.1\/hcrgrunze","article-title":"The effectiveness of anticonvulsants in psychiatric disorders","volume":"10","author":"Grunze","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jpba.2021.114299_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/369707","article-title":"Markedly elevated carbamazepine-10,11-epoxide\/carbamazepine ratio in a fatal carbamazepine ingestion","volume":"2015","author":"Russell","year":"2015","journal-title":"Case Rep. Med."},{"issue":"7","key":"10.1016\/j.jpba.2021.114299_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/17512433.2018.1486707","article-title":"Carbamazepine adverse drug reactions","volume":"11","author":"Fricke-Galindo","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.jpba.2021.114299_bib0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/14656566.2016.1168399","article-title":"Carbamazepine-related antiepileptic drugs for the treatment of epilepsy - a comparative review","volume":"17","author":"Gierbolini","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"Suppl 1","key":"10.1016\/j.jpba.2021.114299_bib0030","first-page":"S81","article-title":"A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012","volume":"18","author":"Tolou-Ghamari","year":"2013","journal-title":"J. Res. Med. Sci."},{"issue":"11","key":"10.1016\/j.jpba.2021.114299_bib0035","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/aps.2012.135","article-title":"The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.jpba.2021.114299_bib0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin. Neuropharmacol."},{"issue":"15","key":"10.1016\/j.jpba.2021.114299_bib0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2217\/pgs.14.142","article-title":"Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy","volume":"15","author":"Zhu","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.jpba.2021.114299_bib0050","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007691-199812000-00012","article-title":"Carbamazepine-10,11-epoxide in therapeutic drug monitoring","volume":"20","author":"Potter","year":"1998","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.jpba.2021.114299_bib0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00007691-200306000-00021","article-title":"How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples?","volume":"25","author":"Hermida","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2021.114299_bib0060","series-title":"Handbook of Drug Monitoring Methods: Therapeutics and Drugs of Abuse","first-page":"133","article-title":"Interferences with measurement of anticonvulsants","author":"Clarke","year":"2008"},{"issue":"4","key":"10.1016\/j.jpba.2021.114299_bib0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1515\/CCLM.2009.105","article-title":"A high-performance liquid chromatography method for the determination of carbamazepine and carbamazepine-10,11-epoxide and its comparison with chemiluminescent immunoassay","volume":"47","author":"Leite","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"issue":"9","key":"10.1016\/j.jpba.2021.114299_bib0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10337-016-3063-7","article-title":"HPLC\u2013DAD method for the quantification of carbamazepine, Oxcarbazepine and their active metabolites in HepaRG cell culture samples","volume":"79","author":"Ferreira","year":"2016","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2021.114299_bib0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/03067310701189083","article-title":"Determination of acidic pharmaceutical products and carbamazepine in roughly primary-treated wastewater by solid phase extraction and gas chromatography-tandem mass spectrometry","volume":"87","author":"Lajeunesse","year":"2007","journal-title":"Int. J. Environ. Anal. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2021.114299_bib0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00216-012-6481-x","article-title":"Analysis of carbamazepine and its five metabolites in serum by large-volume sample stacking-sweeping capillary electrophoresis","volume":"405","author":"Lin","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2021.114299_bib0085","series-title":"Liquid Chromatography-Mass Spectrometry Methods; Approved Guidelines","article-title":"CLSI document C62-a","author":"Wayne","year":"2014"},{"key":"10.1016\/j.jpba.2021.114299_bib0090","series-title":"Guidance for Industry, Bionanalytical Method Validation","year":"2018"},{"key":"10.1016\/j.jpba.2021.114299_bib0095","series-title":"Method Validation: the Detection Limit Experiment, Madison","first-page":"169","article-title":"Basic method validation","author":"Westgard","year":"2008"},{"issue":"1-2","key":"10.1016\/j.jpba.2021.114299_bib0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"3","key":"10.1016\/j.jpba.2021.114299_bib0105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jcla.20460","article-title":"Discordant carbamazepine values between two immunoassays: carbamazepine values determined by ADVIA Centaur correlate better with those determined by LC-MS\/MS than PETINIA assay","volume":"25","author":"McMillin","year":"2011","journal-title":"J. Clin. Lab. Anal."},{"issue":"5","key":"10.1016\/j.jpba.2021.114299_bib0110","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1309\/AJCPFAHVB26VVVTE","article-title":"Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays","volume":"133","author":"McMillin","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.jpba.2021.114299_bib0115","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1081\/JLC-120021762","article-title":"LC\u2013MS\/MS determination of carbamazepine, pindolol, and theophylline in human serum","volume":"26","author":"Abdel\u2010Hamid","year":"2003","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"issue":"1","key":"10.1016\/j.jpba.2021.114299_bib0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpba.2004.11.058","article-title":"Liquid chromatography\/tandem mass spectrometry for the determination of carbamazepine and its main metabolite in rat plasma utilizing an automated blood sampling system","volume":"38","author":"Zhu","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1\u20132","key":"10.1016\/j.jpba.2021.114299_bib0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2005.09.019","article-title":"Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma","volume":"828","author":"Breton","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.jpba.2021.114299_bib0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jpba.2011.07.019","article-title":"Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"56","author":"Kim","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jpba.2021.114299_bib0135","first-page":"443","article-title":"Effects of chronic exposure to carbamazepine onhematological parameters in Cyprinus carpio","volume":"19","author":"Rezaei","year":"2017","journal-title":"Iran. J. Fish. Sci."},{"issue":"1","key":"10.1016\/j.jpba.2021.114299_bib0140","first-page":"85","article-title":"[Carbamazepine induced hyponatremia]","volume":"27","author":"Inamura","year":"1999","journal-title":"No Shinkei Geka"},{"issue":"1","key":"10.1016\/j.jpba.2021.114299_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0404.1983.tb04809.x","article-title":"Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?","volume":"68","author":"Tjellesen","year":"1983","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.jpba.2021.114299_bib0150","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1528-1167.2006.00460.x","article-title":"Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine","volume":"47","author":"Mintzer","year":"2006","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.jpba.2021.114299_bib0155","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.19082\/3257","article-title":"Relationship between bone density and biochemical markers of bone among two groups taking carbamazepine and sodium valproate for epilepsy in comparison with healthy individuals in Yazd","volume":"8","author":"Rahimdel","year":"2016","journal-title":"Electron. Physician"},{"key":"10.1016\/j.jpba.2021.114299_bib0160","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.18203\/2319-2003.ijbcp20192201","article-title":"Effect of carbamazepine on the serum level of thyrotropin releasing hormone","volume":"8","author":"Kalsoom","year":"2019","journal-title":"Int. J. Basic Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jpba.2021.114299_bib0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1442-200X.2002.01561.x","article-title":"Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy","volume":"44","author":"Tsukahara","year":"2002","journal-title":"Pediatr. Int."},{"issue":"4","key":"10.1016\/j.jpba.2021.114299_bib0170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.17305\/bjbms.2012.2445","article-title":"Effects of carbamazepine on serum parathormone, 25- hydroxyvitamin D, bone specific alkaline phosphatase, C-telopeptide, and osteocalcin levels in healthy rats","volume":"12","author":"Kir","year":"2012","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"5","key":"10.1016\/j.jpba.2021.114299_bib0175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/08830738060210050101","article-title":"Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy","volume":"21","author":"Tekgul","year":"2006","journal-title":"J. Child Neurol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:21Z","timestamp":1760001261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521004106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":35,"alternative-id":["S0731708521004106"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114299","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of serum carbamazepine and its metabolite by validated tandem mass spectrometric method and the effect of carbamazepine on various hematological and biochemical parameters","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114299"}}